Clinical Study for AL-CM

Zhejiang University

Status: Enrolling

Conditions: Immunoglobulin Light Amyloidosis Cardiomyopathy

Treatments: Drug: current treatment of AL-CM

Study type: Observational

Funder types: Other

Identifiers

NCT04924998

2021-0133

Details and patient eligibility

About

In this study, patients diagnosed with Al-CM were selected to observe the effect of treatment and conduct long-term follow-up.

Enrollment: 400 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged 18-90 years, regardless of gender, diagnosed with Al-CM at the Second Affiliated Hospital of Zhejiang University School of Medicine;
• Patients have the ability to understand the test, can cooperate with investigators.

Exclusion criteria

• Unable to understand or unwilling to fill in informed consent forms or follow visitors

Trial design

400 participants in 1 patient group

AL-CM

Treatment:

Drug: current treatment of AL-CM